Pune-based startup DeepTek, a leading medical imaging AI company, has received a significant recommendation from the World Health Organization (WHO) for its Chest X-ray AI solution for TB screening.
In its latest policy guidance, WHO recommended the solution as meeting the performance standards for Computer-Aided Detection (CAD) software
used in tuberculosis (TB) screening across both community and facility-based screening
settings.
This recommendation underscores the solution’s clinical reliability, global scalability, and real-world impact—making it one of the few AI tools globally validated for identifying presumptive TB cases rapidly and accurately, particularly in low-resource settings.
In 2022, 10.6 million people were diagnosed with TB, with the highest burden seen in South-East Asia, Africa, and the Western Pacific. These regions often face a shortage of radiologists and fragmented screening systems, leading to delayed diagnosis and treatment.
DeepTek’s Chest X-ray AI solution addresses this challenge head-on by delivering rapid analysis of chest X-rays in under a minute, even in remote areas without internet connectivity, making early intervention possible at scale.
DeepTek’s Chest X-ray AI solution is certified by both the US FDA and EU CE MDR. Beyond detecting tuberculosis, it identifies over 21 other critical lung abnormalities—including nodules, masses, and pneumothorax—making it highly versatile for public health programs and routine lung screenings. A key differentiator of our solution is its ability to interpret pediatric chest X-rays for children aged four and above.
DeepTek’s platform supports end-to-end patient management across the TB screening workflow. Digital X-ray machines are used to capture chest scans, which are analysed by DeepTek’s AI engine to generate TB risk predictions in under a minute. The system operates seamlessly even in offline settings, with data securely synced to the cloud once connectivity is restored.
